-
Mashup Score: 21
WINREVAIR met primary endpoint of time to first morbidity or mortality event for the treatment of patients with pulmonary arterial hypertension (PAH) functional class III or IV at high risk of mortality Study to be stopped early and participants will be offered the opportunity to receive WINREVAIR Second positive phase 3 trial adds to growing body of evidence for WINREVAIR, an activin signaling inhibitor therapy that targets an underlying cause of PAH Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today positive topline results from the Phase 3 ZENITH study evaluating WINREVAIR (sotatercept-csrk) in adults with pulmonary arterial hypertension (PAH, WHO* Group 1) functional class (FC) III or IV at high risk of mortality. ZENITH met its primary endpoint of time to first morbidity or mortality event (all-cause death, lung transplantation, or PAH worsening related hospitalization of ≥ 24 hours). In the study, WINREVAIR demonstrated a statistically
Source: www.merck.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 21
WINREVAIR met primary endpoint of time to first morbidity or mortality event for the treatment of patients with pulmonary arterial hypertension (PAH) functional class III or IV at high risk of mortality Study to be stopped early and participants will be offered the opportunity to receive WINREVAIR Second positive phase 3 trial adds to growing body of evidence for WINREVAIR, an activin signaling inhibitor therapy that targets an underlying cause of PAH Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today positive topline results from the Phase 3 ZENITH study evaluating WINREVAIR (sotatercept-csrk) in adults with pulmonary arterial hypertension (PAH, WHO* Group 1) functional class (FC) III or IV at high risk of mortality. ZENITH met its primary endpoint of time to first morbidity or mortality event (all-cause death, lung transplantation, or PAH worsening related hospitalization of ≥ 24 hours). In the study, WINREVAIR demonstrated a statistically
Source: www.merck.comCategories: General Medicine News, PayerTweet-
Today, we shared new topline results from a Phase 3 study in #PulmonaryArterialHypertension (#PAH). Learn more here: https://t.co/juNEFHO6Xj https://t.co/ZDqMQZnUnb
-
-
Mashup Score: 15
WELIREG is the first and only systemic therapy approved in China for adult patients with certain VHL disease-associated tumors Decision marks first approval for WELIREG in China and 17th approval of WELIREG for these patients globally Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the National Medical Products Administration (NMPA) in China has approved WELIREG ® (belzutifan), for the treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas or pancreatic neuroendocrine tumors (pNET), not requiring immediate surgery. WELIREG is a first-in-class oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor and is the first and only approved HIF-2α inhibitor in China. This approval is based on objective response rate (ORR) and median duration of response (DOR) results from the Phase 2 LITESPARK-004 trial and is the 17th approval
Source: www.merck.comCategories: General Medicine News, PayerTweet-
We’re committed to helping more patients with certain VHL disease-associated tumors around the world. Learn more about our latest #oncology approval in China: https://t.co/HylzDlKHT7 https://t.co/EaU8XZC3u0
-
-
Mashup Score: 14
New research across a broad range of hematologic malignancies to be featured during the meeting, including presentations for investigational assets zilovertamab vedotin and nemtabrutinib Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that new data for approved and investigational medicines across multiple hematologic malignancies will be presented at the American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego from Dec. 7-10. Data being shared at the meeting will showcase the company’s continued progress in advancing clinical research for Merck’s expanding and diverse pipeline of investigational candidates, with more than 20 abstracts being presented. “The innovative research that will be presented at this year’s ASH highlights our robust clinical development program and our commitment to exploring novel modalities and therapeutic targets, as we work to improve outcomes and address unmet needs for people with hematologic
Source: www.merck.comCategories: General Medicine News, PayerTweet-
We’re pleased to highlight new data across our #hematology portfolio and pipeline for hematologic malignancies at #ASH24. Learn more about our latest scientific research: https://t.co/TICcBQC0vN https://t.co/NXwa01dcjp
-
-
Mashup Score: 30Merck Announces Phase 3 Trial of Subcutaneous Pembrolizumab With Berahyaluronidase Alfa Met Primary Endpoints - Merck.com - 8 day(s) ago
Investigational subcutaneous pembrolizumab and berahyaluronidase alfa, in combination with chemotherapy, demonstrates noninferior pharmacokinetics compared to intravenous KEYTRUDA in combination with chemotherapy in adults with metastatic non-small cell lung cancer Merck to discuss results from MK-3475A-D77 study with regulatory authorities worldwide Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive topline results from the pivotal Phase 3 MK-3475A-D77 trial. The trial is evaluating the noninferiority of subcutaneous administration of pembrolizumab, Merck’s anti-PD-1 therapy, available for intravenous use as KEYTRUDA ® , together with berahyaluronidase alfa, a hyaluronidase variant developed and manufactured by Alteogen Inc. (MK-3475A; “subcutaneous pembrolizumab”), administered with chemotherapy versus intravenous (IV) KEYTRUDA administered with chemotherapy for the first-line treatment of adult patients with metastatic non-small cell
Source: www.merck.comCategories: General Medicine News, PayerTweet-
We’re committed to advancing #oncology research for patients. Learn more about our latest Phase 3 results from our subcutaneous immunotherapy development program: https://t.co/dHSwmrlfak https://t.co/ENmZ6Bxrqs
-
-
Mashup Score: 30Merck Announces Phase 3 Trial of Subcutaneous Pembrolizumab With Berahyaluronidase Alfa Met Primary Endpoints - Merck.com - 8 day(s) ago
Investigational subcutaneous pembrolizumab and berahyaluronidase alfa, in combination with chemotherapy, demonstrates noninferior pharmacokinetics compared to intravenous KEYTRUDA in combination with chemotherapy in adults with metastatic non-small cell lung cancer Merck to discuss results from MK-3475A-D77 study with regulatory authorities worldwide Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive topline results from the pivotal Phase 3 MK-3475A-D77 trial. The trial is evaluating the noninferiority of subcutaneous administration of pembrolizumab, Merck’s anti-PD-1 therapy, available for intravenous use as KEYTRUDA ® , together with berahyaluronidase alfa, a hyaluronidase variant developed and manufactured by Alteogen Inc. (MK-3475A; “subcutaneous pembrolizumab”), administered with chemotherapy versus intravenous (IV) KEYTRUDA administered with chemotherapy for the first-line treatment of adult patients with metastatic non-small cell
Source: www.merck.comCategories: General Medicine News, PayerTweet-
We’re committed to advancing #oncology research for patients. Learn more about our latest Phase 3 results from our subcutaneous immunotherapy development program: https://t.co/dHSwmrlfak https://t.co/ENmZ6Bxrqs
-
-
Mashup Score: 1
KENILWORTH, N.J., Feb. 4, 2021 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, today affirmed its position regarding use of ivermectin during the COVID-19 pandemic. Company scientists continue to carefully examine the findings of all available and emerging studies of ivermectin for the treatment of COVID-19 for evidence of efficacy […]
Source: www.merck.comCategories: General Medicine News, Hem/OncsTweet-
@VPrasadMDMPH Ivermectin is made by the big pharma Merck( who these folks hate) , why would they withhold selling it and making billions if it was effective? Just mass hysteria and conspiracy theories.. https://t.co/5Z4zYCJ18p
-
-
Mashup Score: 13
Opinion granted based on positive overall survival results from the IND.227/KEYNOTE-483 trial Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending approval of KEYTRUDA ® (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with pemetrexed and platinum chemotherapy, for the first-line treatment of adult patients with unresectable non-epithelioid malignant pleural mesothelioma (MPM). “The CHMP’s positive opinion marks an important milestone for patients in Europe with non-epithelioid mesothelioma, who experience worse survival outcomes than patients with epithelioid mesothelioma,” said Dr. Gregory Lubiniecki, vice president, oncology clinical research, Merck Research Laboratories. “The positive CHMP opinion moves us closer to offering a new first-line treatment option with a proven overall survival benefit for
Source: www.merck.comCategories: General Medicine News, PayerTweet-
Today, we announced a CHMP opinion recommending approval of our treatment for certain patients with unresectable advanced or metastatic pleural #mesothelioma. Learn more: https://t.co/Ja41bUwgzj https://t.co/lqNkiLbW7y
-
-
Mashup Score: 21
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and LaNova Medicines Ltd. (LaNova), a privately held clinical-stage biotechnology company, today announced that Merck has entered into an exclusive global license to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova. “At Merck, we continue to assemble a strong and diversified oncology pipeline spanning differentiated mechanisms and multiple modalities,” said Dr. Dean Y. Li, president, Merck Research Laboratories. “This agreement adds to Merck’s growing oncology pipeline and we look forward to advancing LM-299 with speed and rigor for patients in need.” Under the agreement, LaNova has granted Merck an exclusive global license to develop, manufacture and commercialize LM-299. LaNova will receive an upfront payment of $588 million. LaNova is also eligible to receive up to $2.7 billion in milestone payments associated with the technology transfer,
Source: www.merck.comCategories: General Medicine News, PayerTweet-
Today we announced an exclusive global license to develop, manufacture and commercialize a novel investigational bispecific antibody from LaNova Medicines Ltd. Learn more: https://t.co/BcIoykXBl7 https://t.co/w6YdRA8SFf
-
-
Mashup Score: 21
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and LaNova Medicines Ltd. (LaNova), a privately held clinical-stage biotechnology company, today announced that Merck has entered into an exclusive global license to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova. “At Merck, we continue to assemble a strong and diversified oncology pipeline spanning differentiated mechanisms and multiple modalities,” said Dr. Dean Y. Li, president, Merck Research Laboratories. “This agreement adds to Merck’s growing oncology pipeline and we look forward to advancing LM-299 with speed and rigor for patients in need.” Under the agreement, LaNova has granted Merck an exclusive global license to develop, manufacture and commercialize LM-299. LaNova will receive an upfront payment of $588 million. LaNova is also eligible to receive up to $2.7 billion in milestone payments associated with the technology transfer,
Source: www.merck.comCategories: General Medicine News, PayerTweet-
Today we announced an exclusive global license to develop, manufacture and commercialize a novel investigational bispecific antibody from LaNova Medicines Ltd. Learn more: https://t.co/BcIoykXBl7 https://t.co/w6YdRA8SFf
-
Today, we shared new topline results from a Phase 3 study in #PulmonaryArterialHypertension (#PAH). Learn more here: https://t.co/juNEFHO6Xj https://t.co/ZDqMQZnUnb